Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial-Reference-Cited by-同舟云学术

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Published:2016-03 Issue:3 Volume:17 Page:378-388
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Armstrong Andrew J,Halabi Susan,Eisen Tim,Broderick Samuel,Stadler Walter M,Jones Robert J,Garcia Jorge A,Vaishampayan Ulka N,Picus Joel,Hawkins Robert E,Hainsworth John D,Kollmannsberger Christian K,Logan Theodore F,Puzanov Igor,Pickering Lisa M,Ryan Christopher W,Protheroe Andrew,Lusk Christine M,Oberg Sadie,George Daniel J

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Therapy for non-clear cell histologies in renal cancer;Bitting;Curr Clin Pharmacol,2011

2. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity;Shuch;Eur Urol,2015

3. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma;Choueiri;J Clin Oncol,2008

4. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis;Gore;Proc Am Soc Clin Oncol,2007

5. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma;Lee;Ann Oncol,2012

Cited by 354 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

2. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma;Journal of Chemotherapy;2024-09-10

3. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan;International Journal of Clinical Oncology;2024-09-02

4. Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era;International Journal of Clinical Oncology;2024-08-14

5. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma;JAMA Network Open;2024-08-06